KPV vs Larazotide
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
KPV
KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH). Despite its small size — just three amino acids — it retains the anti-inflammatory core activity of its parent molecule without the melanogenic effects. It is one of the most researched peptides for gut inflammation, IBD, and intestinal permeability, with the ability to act locally in the gut when administered orally.
Full profileLarazotide
Larazotide (AT-1001) is a synthetic octapeptide that acts as a tight junction regulator — it competitively blocks zonulin, the primary physiological driver of intestinal permeability ('leaky gut'). It is one of the few compounds studied in human clinical trials specifically for tight junction dysfunction, with Phase 2 data in celiac disease demonstrating reduced intestinal permeability and symptom improvement even in the presence of ongoing gluten exposure.
Full profile| KPV | Larazotide | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Lys-Pro-Val, Alpha-MSH C-terminal tripeptide | Larazotide acetate, AT-1001, INN-202 |
| Evidence | Research-stage | FDA-approved |
| Dosing range | 250mcg–1000mcg mcg, Once or twice daily | 0.25mg–1mg mg, 3x daily (before meals) |
| Administration | Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal | Oral (capsule), Subcutaneous injection (research use) |
| Key side effects | Generally well-tolerated, Mild injection site irritation, Transient headache (uncommon), No melanogenic effects (does not cause tanning unlike full α-MSH) | Headache (most commonly reported adverse event in trials), Nausea (mild), Generally well-tolerated — adverse event rate similar to placebo in clinical trials |
| Cited sources | 3 references | 3 references |
Key differences
- Evidence level differs: KPV is research-stage, while Larazotide is fda-approved.
- Administration: KPV — Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal; Larazotide — Oral (capsule), Subcutaneous injection (research use).
- Dosing units differ: KPV is dosed in mcg, Larazotide in mg — they operate at different scales.
- Frequency: KPV is typically Once or twice daily; Larazotide is 3x daily (before meals).
How each works
KPV
KPV exerts anti-inflammatory effects through melanocortin receptor-independent mechanisms as well as via MC1R and MC3R activation. It downregulates NF-κB, inhibits pro-inflammatory cytokines (TNF-α, IL-1β, IL-8), and reduces neutrophil infiltration in colonic tissue. Uniquely for a peptide, KPV is acid-stable enough to survive gastric transit and reach the intestinal mucosa intact, making oral delivery viable for gut-targeted applications — a significant advantage over most injectable-only peptides.
Larazotide
Zonulin upregulation disrupts the tight junction proteins occludin and claudin, allowing paracellular passage of antigens, LPS, and inflammatory triggers into systemic circulation. Larazotide acts as a tight junction agonist by competitively displacing zonulin from its receptor and directly stabilizing tight junction complexes. The Phase 2b CeD trial (N=342) showed larazotide reduced the ratio of lactulose/mannitol (L/M ratio, standard intestinal permeability marker) and improved GI symptom scores versus placebo in actively-challenged celiac patients.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.